Waltham, Mass.-based Radius Health, a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, recently announced the latest 2019 Medicare Part D coverage for TYMLOS which increased to approximately 26.2 million lives or 64 percent of those enrolled in Medicare Part D plans in the U.S.Effective Jan. 1, 2019, SilverScript Insurance Company (a CVS Caremark company), WellCare Health Plans and Prime Therapeutics will become the latest Medicare Part D prescription drug plan sponsors to cover TYMLOS (abaloparatide) injection for their beneficiaries. Express Scripts, Inc., UnitedHealthcare, Kaiser Permanente and EnvisionRx, among others, have decided to continue Medicare Part D coverage of TYMLOS through 2019. Over the next couple weeks, payers and PBMs will continue to make publicly available their Medicare Part D 2019 drug formularies. Radius plans to provide a detailed update on TYMLOS’ 2019 formulary coverage at the company’s third quarter earnings call in November.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.